OmniAb Investor Presentation Deck

Growth of Partner Programs PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT 21 Active Programs as of 2016(1) Preclinical: 1 Discovery: 20 (1) Estimated at the time of acquisition of OMT, Inc. 305 Active Programs as of 06/30/2023 Preclinical: 15 Phase 2: 2 Phase 1: 22 Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals Phase 3: 1 BLA: 1 Approved: 3 Discovery: 261 6 OmniAb

View entire presentation